{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:48:21Z","timestamp":1768999701293,"version":"3.49.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Trimethylamine-N-oxide (TMAO) is correlated with atherosclerosis and vascular diseases such as coronary heart disease and ischemic stroke. The aim of the study was to investigate whether TMAO levels are different in symptomatic vs. asymptomatic cerebrovascular atherosclerosis.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was a prospective, case\u2013control study, conducted at a tertiary care university hospital. Patients were included if they had large-artery atherosclerosis (TOAST criteria). Symptomatic patients with ischemic stroke were compared with asymptomatic patients. As primary endpoint, TMAO levels on admission were compared between symptomatic and asymptomatic patients. Univariable analysis was performed using Mann\u2013Whitney <jats:italic>U<\/jats:italic> test and multivariable analysis using binary logistic regression. TMAO values were adjusted for glomerular filtration rate (GFR), age, and smoking.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Between 2018 and 2020, 82 symptomatic and asymptomatic patients were recruited. Median age was 70 years; 65% were male. Comparing symptomatic (<jats:italic>n<\/jats:italic> = 42) and asymptomatic (<jats:italic>n<\/jats:italic> = 40) patients, no significant differences were found in univariable analysis in TMAO [3.96 (IQR 2.30\u20136.73) vs. 5.36 (3.59\u20138.68) \u03bcmol\/L; <jats:italic>p<\/jats:italic> = 0.055], GFR [87 (72\u201397) vs. 82 (71\u201390) ml\/min<jats:sup>*<\/jats:sup>1.73 m<jats:sup>2<\/jats:sup>; <jats:italic>p<\/jats:italic> = 0.189] and age [71 (60\u201379) vs. 69 (67\u201375) years; <jats:italic>p<\/jats:italic> = 0.756]. In multivariable analysis, TMAO was not a predictor of symptomatic cerebrovascular disease after adjusting for age and GFR [OR 1.003 (95% CI: 0.941\u20131.070); <jats:italic>p<\/jats:italic> = 0.920]. In a sensitivity analysis, we only analyzed patients with symptomatic stenosis and excluded patients with occlusion of brain-supplying arteries. Again, TMAO was not a significant predictor of symptomatic stenosis [OR 1.039 (0.965\u20131.120), <jats:italic>p<\/jats:italic> = 0.311].<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> TMAO levels could not be used to differentiate between symptomatic and asymptomatic cerebrovascular disease in our study.<\/jats:p>","DOI":"10.3389\/fneur.2021.617944","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T05:51:47Z","timestamp":1616133107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Trimethylamine-N-Oxide Levels Are Similar in Asymptomatic vs. Symptomatic Cerebrovascular Atherosclerosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Miriam","family":"Heyse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Monostori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin V.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Hauke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Dr\u00fcschler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Berberich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Ringleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen G.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibu","family":"Mundiyanapurath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-nutr-071816-064732","article-title":"Trimethylamine N-Oxide, the microbiome, and heart and kidney disease","volume":"37","author":"Zeisel","year":"2017","journal-title":"Annu Re Nutr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/eurheartj\/ehw582","article-title":"Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors","volume":"38","author":"Li","year":"2017","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12937-020-00592-2","article-title":"Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke: a systematic review and dose-response meta-analysis","volume":"19","author":"Farhangi","year":"2020","journal-title":"Nutr J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1283","DOI":"10.1212\/WNL.0000000000005298","article-title":"Elevated trimethylamine N-oxide related to ischemic brain lesions after carotid artery stenting","volume":"90","author":"Wu","year":"2018","journal-title":"Neurology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke."},{"key":"B6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1747-4949.2009.00290.x","article-title":"Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial","volume":"4","author":"Reiff","year":"2009","journal-title":"Int J Stroke."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ene.14253","article-title":"Trimethylamine-N-oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days","volume":"27","author":"Schneider","year":"2020","journal-title":"Eur J Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ab.2014.03.016","article-title":"Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry","volume":"455","author":"Wang","year":"2014","journal-title":"Anal Biochem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ejrad.2015.12.020","article-title":"Cortical vessel sign on susceptibility weighted imaging reveals clinically relevant hypoperfusion in internal carotid artery stenosis","volume":"85","author":"Mundiyanapurath","year":"2016","journal-title":"Eur J Radiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1055\/s-0029-1245336","article-title":"Revision of DEGUM ultrasound criteria for grading internal carotid artery stenoses and transfer to NASCET measurement","volume":"31","author":"Arning","year":"2010","journal-title":"Ultraschall in der Medizin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2288-12-81","article-title":"To test or not to test: preliminary assessment of normality when comparing two independent samples","volume":"12","author":"Rochon","year":"2012","journal-title":"BMC Med Res Methodol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e002699","DOI":"10.1161\/JAHA.115.002699","article-title":"Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack","volume":"4","author":"Yin","year":"2015","journal-title":"J Am Heart Assoc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e22246","DOI":"10.1002\/jbt.22246","article-title":"Trimethylamine N-oxide as a risk marker for ischemic stroke in patients with atrial fibrillation","volume":"33","author":"Liang","year":"2019","journal-title":"J Biochem Mol Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2018.04.015","article-title":"Metabolic products of the intestinal microbiome and extremes of atherosclerosis","volume":"273","author":"Bogiatzi","year":"2018","journal-title":"Atherosclerosis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e015331","DOI":"10.1161\/JAHA.119.015331","article-title":"Gut microbiota-dependent trimethylamine N-oxide and cardiovascular outcomes in patients with prior myocardial infarction: a nested case control study from the PEGASUS-TIMI 54 trial","volume":"9","author":"Gencer","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fneur.2020.00029","article-title":"Dynamic changes and prognostic value of gut microbiota-dependent trimethylamine-N-oxide in acute ischemic stroke","volume":"11","author":"Tan","year":"2020","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.617944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T05:51:49Z","timestamp":1616133109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.617944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":17,"alternative-id":["10.3389\/fneur.2021.617944"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.617944","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"article-number":"617944"}}